Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

Market Cap$129.71B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Gilead Sciences, Inc.Gilead Sciences, Inc.270.62.96%-4.6-

Earnings Call Q4 2024

February 11, 2025 - AI Summary

Strong Revenue Growth: Gilead reported a total product sales increase of 8% year-over-year (YoY) in 2024, reaching $26.8 billion, excluding Veklury. In Q4, total product sales increased by 13% YoY to $7.2 billion. HIV sales grew by 8% to $19.6 billion, with Biktarvy rising 13% YoY.
Lenacapavir Launch and Potential: Gilead is preparing for the mid-2025 launch of lenacapavir for HIV prevention (PrEP), with high expectations for market impact. The drug has received breakthrough therapy designation from the FDA. It is anticipated to redefine the PrEP market, with potential revenue growth expected as access increases, reaching an estimated 75% by the end of the first year.
Impact of Medicare Part D Reform: The anticipated Medicare Part D reform is expected to negatively impact 2025 revenue by approximately $1.1 billion, predominantly affecting HIV sales (around $900 million), leading to flat revenue expectations for the HIV segment in 2025 despite anticipated demand growth.

Exclusive for Stockcircle Pro members

Sign upSign Up
$94.50

Target Price by Analysts

10.2% downsideGilead Sciences Target Price DetailsTarget Price
$242.76

Current Fair Value

130.7% upside

Undervalued by 130.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$129.71 Billion
Enterprise Value$129.71 Billion
Dividend Yield$3.08 (2.95926210607225%)
Earnings per Share$0.38
Beta0.19
Outstanding Shares1,248,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio270.61
PEG1092.37
Price to Sales4.58
Price to Book Ratio2.24
Enterprise Value to Revenue4.51
Enterprise Value to EBIT15.1
Enterprise Value to Net Income270
Total Debt to Enterprise0
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Gilead Sciences, Inc.

CEO: Daniel O'Day